Erbitux Related Published Studies
Well-designed clinical trials related to Erbitux (Cetuximab)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. [2008.10.23]
Platinum-based chemotherapy plus cetuximab in head and neck cancer. [2008.09.11]
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. [2008.08.05]
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. [2008.07.10]
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. [2008.07]
A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. [2008.06]
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. [2008.05.10]
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. [2008.04]
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. [2008.03]
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. [2008.02]
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. [2008.01]
Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. [2007.12.20]
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. [2007.12.01]
Cetuximab for the treatment of colorectal cancer. [2007.11.15]
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. [2006.11.01]
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. [2006.06.20]
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. [2006.02.09]
Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283]. [2005.10.11]
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. [2004.07.22]
Well-designed clinical trials possibly related to Erbitux (Cetuximab)
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). [2008.08.15]
Advances in chemotherapy against advanced or metastatic colorectal cancer. [2008]
Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. [2007.06.01]
Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. [2007.04.11]
Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. [2006.05]
An overview of eastern cooperative oncology group stage III non-small cell lung cancer studies. [2005.04]
Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. [2004.10]
Integration of novel agents in the treatment of colorectal cancer. [2004.09]
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. [2002.02]
Other research related to Erbitux (Cetuximab)
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. [2008.09.15]
The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer. [2008.09]
Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. [2008.09]
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. [2008.08.13]
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. [2008.08]
Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial. [2008.08]
VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. [2008.07.14]
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. [2008.07.08]
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. [2008.07.01]
Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases. [2008.07]
Effect of bortezomib and cetuximab in EGF-stimulated HNSCC. [2008.07]
A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities. [2008.07]
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. [2008.06.15]
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. [2008.06.15]
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. [2008.06.10]
Cetuximab: Its Use in Combination with Radiation Therapy and Chemo-therapy in the Multimodality Treatment of Head and Neck Cancer. [2008.06]
The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice. [2008.06]
Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). [2008.06]
Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer. [2008.05]
EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab? [2008.04]
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. [2008.03.20]
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. [2008.03.17]
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. [2008.03.15]
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. [2008.03.13]
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. [2008.03]
Implications of EGFR PharmDx kit for cetuximab eligibility. [2008.03]
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. [2008.02.13]
Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. [2008.02]
The emerging role of cetuximab in head and neck cancer: a 2007 perspective. [2008.02]
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. [2008.01.20]
An Economic Evaluation of Cetuximab Combined with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. [2008.01.09]
Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. [2008.01]
Cetuximab in non-small cell lung cancer. [2008.01]
Integrating microarray and proteomics data to predict the response on cetuximab in patients with rectal cancer. [2008]
Response to reintroduction of cetuximab in 5 patients with advanced, chemotherapy-resistant, colorectal cancer without progressive disease following first-line therapy with a cetuximab-containing regimen. [2008]
Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. [2007.12.15]
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. [2007.12.10]
First-line single-agent cetuximab in patients with advanced colorectal cancer. [2007.12.10]
Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. [2007.12]
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. [2007.11.20]
Cetuximab efficacy in patients treated routinely in university hospitals. [2007.11]
Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis. [2007.11]
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. [2007.10.22]
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. [2007.10.17]
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. [2007.10.10]
Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. [2007.10.10]
Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia. [2007.10]
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. [2007.09.01]
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. [2007.09.01]
Targeted agents to improve treatment results in colon cancer: bevacizumab and cetuximab. [2007.09]
[Treatment with cetuximab in metastatic colorectal cancer patients who do not express the epidermal growth factor receptor] [2007.09]
A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. [2007.09]
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. [2007.08.20]
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. [2007.08.20]
Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. [2007.08.20]
Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab. [2007.08.01]
Is there a role for cetuximab in non small cell lung cancer? [2007.08.01]
[Cetuximab] [2007.08]
Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. [2007.08]
Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. [2007.08]
Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. [2007.08]
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. [2007.07.24]
In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. [2007.07.01]
Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. [2007.07]
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. [2007.06.01]
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. [2007.06.01]
Cetuximab: clinical results in colorectal cancer. [2007.06]
Cetuximab in squamous cell head and neck carcinomas. [2007.06]
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. [2007.05.28]
Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. [2007.05]
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. [2007.04.23]
Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. [2007.04]
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. [2007.04]
|
